Inside Precision Medicine February 23, 2023
UK drug discovery company C4X Discovery Holdings Plc. has announced the launch of PatientSeek, its precision medicine platform to identify patients most likely to benefit from a medication based on their genetics.
The launch follows its first validation for patient stratification using results from a failed Phase 3 clinical trial into Parkinson’s disease.
The retrospective analysis, conducted by Australia’s Garvan Institute of Medical Research in Sydney, identified a subgroup of patients that responded to treatment despite the trial’s failure to reach its clinical endpoint overall.
Findings from the study will be submitted to a peer-reviewed journal in due course, C4XD said.
“We believe the PatientSeek platform has huge potential to unlock precision medicine approaches...
Today's Sponsors
Today's Sponsor